Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
CVL-354
Другие языки:

    CVL-354

    Подписчиков: 0, рейтинг: 0
    CVL-354
    Clinical data
    Routes of
    administration    		 Oral administration
    Drug class Opioid antagonist; κ-Opioid receptor antagonist

    CVL-354 is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders (e.g., opioid use disorder). It acts as a selective antagonist of the κ-opioid receptor. The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor. CVL-354 is taken by mouth. It was originated by Pfizer and is under development by Cerevel Therapeutics. As of September 2022, CVL-354 is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.

    See also



    Новое сообщение